Blood Res.  2024;59:12. 10.1007/s44313-024-00012-y.

Genomic testing for germline predisposition to hematologic malignancies

• Hwang S

• KMID: 2562516
• DOI: http://doi.org/10.1007/s44313-024-00012-y

Abstract

Germline predisposition (GPD) to hematological malignancies has gained interest because of the increased use of genetic testing in this field. Recent studies have suggested that GPD is underrecognized and requires appropriate genomic testing for an accurate diagnosis. Identification of GPD significantly affects patient management and has diverse implications for family members. This review discusses the reasons for testing GPD in hematologic malignancies and explores the considerations necessary for appropriate genomic testing. The aim is to provide insights into how these genetic insights can inform treatment strategies and genetic counseling, ultimately enhancing patient care.

Keyword

Germline predisposition; Hematologic malignancies; Genomic testing; Myeloid neoplasms; Nextgeneration sequencing

Reference

1. Duncavage EJ, Bagg A, Hasserjian RP, et al. 2022; Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 140:2228–47. DOI: 10.1182/blood.2022015853. PMID: 36130297. PMCID: PMC10488320.

2. Walsh M, Wu G, Edmonson M, et al. 2014; Incidence of germline mutations in cancer-predisposition genes in children with hematologic malignancies: A report from the pediatric cancer genome project. Blood. 124:127. DOI: 10.1182/blood.V124.21.127.127.

3. Vlachos A, Rosenberg PS, Atsidaftos E, et al. 2012; Incidence of neoplasia in Diamond-Blackfan anemia: A report from the Diamond-Blackfan anemia registry. Blood. 119:3815–9. DOI: 10.1182/blood-2011-08-375972. PMID: 22362038. PMCID: PMC3335385.

4. Khoury JD, Solary E, Abla O, et al. 2022; The 5th Edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia. 36:1703–19. DOI: 10.1038/s41375-022-01613-1. PMID: 35732831. PMCID: PMC9252913.

5. Arber DA, Orazi A, Hasserjian RP, et al. 2022; International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood. 140:1200–28. DOI: 10.1182/blood.2022015850. PMID: 35767897. PMCID: PMC9479031.

6. Furutani E, Shimamura A. 2017; Germline genetic predisposition to hematologic malignancy. J Clin Oncol. 35:1018. DOI: 10.1200/JCO.2016.70.8644. PMID: 28297620. PMCID: PMC5559882.

7. Baliakas P, Tesi B, Wartiovaara-Kautto U, et al. 2019; Nordic guidelines for germline predisposition to myeloid neoplasms in adults: Recommendations for genetic diagnosis, clinical management and follow-up. Hemasphere. 3:e321. DOI: 10.1097/HS9.0000000000000321. PMID: 31976490. PMCID: PMC6924562. PMID: e012695ca5da41d3893550e56ca30089.

8. Feurstein S, Trottier AM, Estrada-Merly N, et al. 2022; Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 140:2533–48. DOI: 10.1182/blood.2022015790. PMID: 35969835. PMCID: PMC9918848.

9. Zhang J, Walsh MF, Wu G, et al. 2015; Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 373:2336–46. DOI: 10.1056/NEJMoa1508054. PMID: 26580448. PMCID: PMC4734119.

10. Döhner H, Wei AH, Appelbaum FR, et al. 2022; Diagnosis and management of aml in adults: 2022 recommendations from an international expert panel on behalf of the eln. Blood. 140:1345–77. DOI: 10.1182/blood.2022016867. PMID: 35797463.

11. Borriello A, Locasciulli A, Bianco A, et al. 2007; A novel leu153ser mutation of the Fanconi anemia fancd2 gene is associated with severe chemotherapy toxicity in a pediatric t-cell acute lymphoblastic leukemia. Leukemia. 21:72–8. DOI: 10.1038/sj.leu.2404468. PMID: 17096012.

12. Ebens CL, MacMillan ML, Wagner JE. 2017; Hematopoietic cell transplantation in Fanconi anemia: Current evidence, challenges and recommendations. Expert Rev Hematol. 10:81–97. DOI: 10.1080/17474086.2016.1268048. PMID: 27929686. PMCID: PMC6089510.

13. McReynolds LJ, Rafati M, Wang Y, et al. 2022; Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. Blood. 140:909–21. DOI: 10.1182/blood.2022016508. PMID: 35776903. PMCID: PMC9412004.

14. Grossman J, Cuellar-Rodriguez J, Gea-Banacloche J, et al. 2014; Nonmyeloablative allogeneic hematopoietic stem cell transplantation for gata2 deficiency. Biol Blood Marrow Transplant. 20:1940–8. DOI: 10.1016/j.bbmt.2014.08.004. PMID: 25111582. PMCID: PMC4253545.

15. Xiao H, Shi J, Luo Y, et al. 2011; First report of multiple cebpa mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 117:5257–60. DOI: 10.1182/blood-2010-12-326322. PMID: 21403128.

16. Kobayashi S, Kobayashi A, Osawa Y, et al. 2017; Donor cell leukemia arising from preleukemic clones with a novel germline ddx41 mutation after allogenic hematopoietic stem cell transplantation. Leukemia. 31:1020–2. DOI: 10.1038/leu.2017.44. PMID: 28194039.

17. Galera P, Hsu AP, Wang W, et al. 2018; Donor-derived mds/aml in families with germline gata2 mutation. Blood. 132:1994–8. DOI: 10.1182/blood-2018-07-861070. PMID: 30232126. PMCID: PMC6213320.

18. Rojek K, Nickels E, Neistadt B, et al. 2016; Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donorderived malignancy. Biol Blood Marrow Transplant. 22:2100–3. DOI: 10.1016/j.bbmt.2016.08.002. PMID: 27497531. PMCID: PMC5592729.

19. Robson ME, Storm CD, Weitzel J, et al. 2010; American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol. 28:893–901. DOI: 10.1200/JCO.2009.27.0660. PMID: 20065170.

20. Deroin L, de Andrade Silva MC, Petras K, et al. 2022; Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation. 43:950–62. DOI: 10.1002/humu.24374. PMID: 35419889. PMCID: PMC9177640.

21. Padron E, Ball MC, Teer JK, et al. 2018; Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 131:2402–5. DOI: 10.1182/blood-2018-01-827881. PMID: 29661788. PMCID: PMC5969383.

22. Theda C, Hwang SH, Czajko A, et al. 2018; Quantitation of the cellular content of saliva and buccal swab samples. Sci Rep. 8:6944. DOI: 10.1038/s41598-018-25311-0. PMID: 29720614. PMCID: PMC5932057. PMID: 1bf2092b0a9446bd8819ebbc277bd7e9.

23. Wong JC, Bryant V, Lamprecht T, et al. 2018; Germline samd9 and samd9l mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI insight. 3:e121086. DOI: 10.1172/jci.insight.121086. PMID: 30046003. PMCID: PMC6124395.

24. DiStefano MT, Goehringer S, Babb L, et al. 2022; The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 24:1732–42. DOI: 10.1016/j.gim.2022.04.017. PMID: 35507016. PMCID: PMC7613247.

25. Tawana K, Brown AL, Churpek JE. 2022; Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: Current strategies and challenges. Br J Haematol. 196:1293–310. DOI: 10.1111/bjh.17855. PMID: 34658019.

26. Rio-Machin A, Vulliamy T, Hug N, et al. 2020; The complex genetic landscape of familial mds and aml reveals pathogenic germline variants. Nat Commun. 11:1044. DOI: 10.1038/s41467-020-14829-5. PMID: 32098966. PMCID: PMC7042299. PMID: a25bb12eaf454851a551304c03cbab09.

27. Makishima H, Bowman TV, Godley LA. 2023; Ddx41-associated susceptibility to myeloid neoplasms. Blood. 141:1544–52. DOI: 10.1182/blood.2022017715. PMID: 36455200. PMCID: PMC10356560.

28. Duployez N, Largeaud L, Duchmann M, et al. 2022; Prognostic impact of ddx41 germline mutations in intensively treated acute myeloid leukemia patients: An alfa-filo study. Blood. 140:756–68. DOI: 10.1182/blood.2021015328. PMID: 35443031. PMCID: PMC9389637.

29. Choi E-J, Cho Y-U, Hur E-H, et al. 2022; Unique ethnic features of ddx41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica. 107:510. DOI: 10.3324/haematol.2020.270553. PMID: 33626862. PMCID: PMC8804579.

30. Makishima H, Saiki R, Nannya Y, et al. 2023; Germ line ddx41 mutations define a unique subtype of myeloid neoplasms. Blood. 141:534–49. DOI: 10.1182/blood.2022018221. PMID: 36322930.

31. Brown AL, Arts P, Carmichael CL, et al. 2020; Runx1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed aml. Blood Adv. 4:1131–44. DOI: 10.1182/bloodadvances.2019000901. PMID: 32208489. PMCID: PMC7094007.

32. Liu PP, Cunningham L, Merguerian MD, et al. 2023; Natural history study of patients with familial platelet disorder with myeloid malignancy. Blood. 142(25):2146–58. DOI: 10.1182/blood.2023019746. PMID: 37738626.

33. Homan CC, Scott HS, Brown AL. 2023; Hereditary platelet disorders associated with germ line variants in runx1, etv6, and ankrd26. Blood. 141:1533–43. DOI: 10.1182/blood.2022017735. PMID: 36626254. PMCID: PMC10651873.

34. Sullivan MJ, Palmer EL, Botero JP. 2022; Ankrd26-related thrombocytopenia and predisposition to myeloid neoplasms. Curr Hematol Malig Rep. 17:105–12. DOI: 10.1007/s11899-022-00666-4. PMID: 35751752.

35. Wlodarski MW, Hirabayashi S, Pastor V, et al. 2016; Prevalence, clinical characteristics, and prognosis of gata2-related myelodysplastic syndromes in children and adolescents. Blood. 127:1387–97. DOI: 10.1182/blood-2015-09-669937. PMID: 26702063.

36. Buonocore F, Kühnen P, Suntharalingham JP, et al. 2017; Somatic mutations and progressive monosomy modify samd9-related phenotypes in humans. J Clin Investig. 127:1700–13. DOI: 10.1172/JCI91913. PMID: 28346228. PMCID: PMC5409795.

37. Shima H, Koehler K, Nomura Y, et al. 2018; Two patients with mirage syndrome lacking haematological features: role of somatic second-site reversion samd9 mutations. J Med Genet. 55(2):81–5. DOI: 10.1136/jmedgenet-2017-105020. PMID: 29175836.

38. Li MM, Chao E, Esplin ED, et al. 2020; Points to consider for reporting of germline variation in patients undergoing tumor testing: A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 22:1142–8. DOI: 10.1038/s41436-020-0783-8. PMID: 32321997.

39. Drazer MW, Kadri S, Sukhanova M, et al. 2018; Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2:146–50. DOI: 10.1182/bloodadvances.2017013037. PMID: 29365323. PMCID: PMC5787862.

40. Kanagal-Shamanna R. 2021; The emerging role of hematopathologists and molecular pathologists in detection, monitoring, and management of myeloid neoplasms with germline predisposition. Curr Hematol Malig Rep. 16:336–44. DOI: 10.1007/s11899-021-00636-2. PMID: 34028637.

41. Reinig EF, Rubinstein JD, Patil AT, et al. 2023; Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis. Leukemia. 37:1589–99. DOI: 10.1038/s41375-023-01955-4. PMID: 37393344. PMCID: PMC10529926.

42. Reilly CR, Shimamura A. 2023; Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: Biological insights and clinical advances. Blood. 141:1513–23. DOI: 10.1182/blood.2022017739. PMID: 36542827.

43. Boocock GR, Morrison JA, Popovic M, et al. 2003; Mutations in sbds are associated with Shwachman-Diamond syndrome. Nat Genet. 33:97–101. DOI: 10.1038/ng1062. PMID: 12496757.

44. Richards S, Aziz N, Bale S, et al. 2015; Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. 17:405–23. DOI: 10.1038/gim.2015.30. PMID: 25741868. PMCID: PMC4544753.

45. Li MM, Datto M, Duncavage EJ, et al. 2017; Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and College of American Pathologists. J Mol Diagn. 19:4–23. DOI: 10.1016/j.jmoldx.2016.10.002. PMID: 27993330. PMCID: PMC5707196.

46. Feurstein S, Hahn CN, Mehta N, et al. 2022; A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genet Med. 24:931–54. DOI: 10.1016/j.gim.2021.12.008. PMID: 35063349.

47. Moody EW, Vagher J, Espinel W, et al. 2019; Comparison of somatic and germline variant interpretation in hereditary cancer genes. JCO Precis Oncol. 3:1–8. DOI: 10.1200/PO.19.00144. PMID: 35100725.

48. Pauley K, Koptiuch C, Greenberg S, et al. 2022; Discrepancies between tumor genomic profiling and germline genetic testing. ESMO open. 7:100526. DOI: 10.1016/j.esmoop.2022.100526. PMID: 35780590. PMCID: PMC9511791.

49. Feurstein S, Luo X, Shah M, et al. 2022; Revision of runx1 variant curation rules. Blood Adv. 6:4726–30. DOI: 10.1182/bloodadvances.2022008017. PMID: 35764482. PMCID: PMC9631670.

50. Luo X, Feurstein S, Mohan S, et al. 2019; Clingen myeloid malignancy variant curation expert panel recommendations for germline runx1 variants. Blood Adv. 3:2962–79. DOI: 10.1182/bloodadvances.2019000644. PMID: 31648317. PMCID: PMC6849945.

51. Fortuno C, Lee K, Olivier M, et al. 2021; Specifications of the ACMG/AMP variant interpretation guidelines for germline tp53 variants. Hum Mutat. 42:223–36. DOI: 10.1002/humu.24152. PMID: 33300245. PMCID: PMC8374922.

52. Gelb BD, Cavé H, Dillon MW, et al. 2018; Clingen's rasopathy expert panel consensus methods for variant interpretation. Genet Med. 20:1334–45. DOI: 10.1038/gim.2018.3. PMID: 29493581. PMCID: PMC6119537.

53. Clark A, Thomas S, Hamblin A, et al. 2023; Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), Cangene-Canvar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT). Br J Haematol. 201:35–44. DOI: 10.1111/bjh.18682. PMID: 36786081.

54. Porter CC, Druley TE, Erez A, et al. 2017; Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res. 23:e14–22. DOI: 10.1158/1078-0432.CCR-17-0428. PMID: 28572263.